426 related articles for article (PubMed ID: 28378930)
1. Hepatic FXR/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice.
Kim KH; Choi S; Zhou Y; Kim EY; Lee JM; Saha PK; Anakk S; Moore DD
Hepatology; 2017 Aug; 66(2):498-509. PubMed ID: 28378930
[TBL] [Abstract][Full Text] [Related]
2. Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice.
Li G; Kong B; Zhu Y; Zhan L; Williams JA; Tawfik O; Kassel KM; Luyendyk JP; Wang L; Guo GL
Toxicol Appl Pharmacol; 2013 Oct; 272(2):299-305. PubMed ID: 23811326
[TBL] [Abstract][Full Text] [Related]
3. Farnesoid X receptor is essential for normal glucose homeostasis.
Ma K; Saha PK; Chan L; Moore DD
J Clin Invest; 2006 Apr; 116(4):1102-9. PubMed ID: 16557297
[TBL] [Abstract][Full Text] [Related]
4. Defective FXR-SHP Regulation in Obesity Aberrantly Increases
Seok S; Sun H; Kim YC; Kemper B; Kemper JK
Diabetes; 2021 Mar; 70(3):733-744. PubMed ID: 33328206
[TBL] [Abstract][Full Text] [Related]
5. Small heterodimer partner deletion prevents hepatic steatosis and when combined with farnesoid X receptor loss protects against type 2 diabetes in mice.
Akinrotimi O; Riessen R; VanDuyne P; Park JE; Lee YK; Wong LJ; Zavacki AM; Schoonjans K; Anakk S
Hepatology; 2017 Dec; 66(6):1854-1865. PubMed ID: 28586124
[TBL] [Abstract][Full Text] [Related]
6. Xenobiotic Nuclear Receptor Signaling Determines Molecular Pathogenesis of Progressive Familial Intrahepatic Cholestasis.
Kim KH; Choi JM; Li F; Arizpe A; Wooton-Kee CR; Anakk S; Jung SY; Finegold MJ; Moore DD
Endocrinology; 2018 Jun; 159(6):2435-2446. PubMed ID: 29718219
[TBL] [Abstract][Full Text] [Related]
7. Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model.
Yan Y; Sha Y; Huang X; Yuan W; Wu F; Hong J; Fang S; Huang B; Hu C; Wang B; Zhang X
Obes Surg; 2019 Sep; 29(9):2912-2922. PubMed ID: 31079286
[TBL] [Abstract][Full Text] [Related]
8. Deficiency of Both Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Exacerbated Liver Fibrosis in Mice.
Ferrell JM; Pathak P; Boehme S; Gilliland T; Chiang JYL
Hepatology; 2019 Sep; 70(3):955-970. PubMed ID: 30664797
[TBL] [Abstract][Full Text] [Related]
9. Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4.
Deng W; Fan W; Tang T; Wan H; Zhao S; Tan Y; Oware KA; Tan J; Li J; Qu S
Oxid Med Cell Longev; 2022; 2022():3589525. PubMed ID: 35251469
[TBL] [Abstract][Full Text] [Related]
10. Targeting FXR in Cholestasis.
Keitel V; Dröge C; Häussinger D
Handb Exp Pharmacol; 2019; 256():299-324. PubMed ID: 31201556
[TBL] [Abstract][Full Text] [Related]
11. Farnesoid X receptor activation mediates head-to-tail chromatin looping in the Nr0b2 gene encoding small heterodimer partner.
Li G; Thomas AM; Hart SN; Zhong X; Wu D; Guo GL
Mol Endocrinol; 2010 Jul; 24(7):1404-12. PubMed ID: 20444884
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver.
Huang J; Iqbal J; Saha PK; Liu J; Chan L; Hussain MM; Moore DD; Wang L
Hepatology; 2007 Jul; 46(1):147-57. PubMed ID: 17526026
[TBL] [Abstract][Full Text] [Related]
13. Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis.
Anakk S; Watanabe M; Ochsner SA; McKenna NJ; Finegold MJ; Moore DD
J Clin Invest; 2011 Jan; 121(1):86-95. PubMed ID: 21123943
[TBL] [Abstract][Full Text] [Related]
14. Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH.
Bjursell M; Wedin M; Admyre T; Hermansson M; Böttcher G; Göransson M; Lindén D; Bamberg K; Oscarsson J; Bohlooly-Y M
PLoS One; 2013; 8(5):e64721. PubMed ID: 23700488
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X receptor agonist decreases lipid accumulation by promoting hepatic fatty acid oxidation in db/db mice.
Liu Y; Song A; Yang X; Zhen Y; Chen W; Yang L; Wang C; Ma H
Int J Mol Med; 2018 Sep; 42(3):1723-1731. PubMed ID: 29901078
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1.
Wu GY; Rui C; Chen JQ; Sho E; Zhan SS; Yuan XW; Ding YT
Cell Physiol Biochem; 2017; 44(4):1651-1664. PubMed ID: 29216638
[TBL] [Abstract][Full Text] [Related]
17. The contribution of small heterodimer partner to the occurrence and progression of cholestatic liver injury.
Wei S; Wang R; Chen L; Jing M; Li H; Zheng R; Zhu Y; Zhao Y
J Gastroenterol Hepatol; 2024 Jun; 39(6):1134-1144. PubMed ID: 38615196
[TBL] [Abstract][Full Text] [Related]
18. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol.
Chow EC; Magomedova L; Quach HP; Patel R; Durk MR; Fan J; Maeng HJ; Irondi K; Anakk S; Moore DD; Cummins CL; Pang KS
Gastroenterology; 2014 Apr; 146(4):1048-59. PubMed ID: 24365583
[TBL] [Abstract][Full Text] [Related]
20. Novel ι-Carrageenan Tetrasaccharide Alleviates Liver Lipid Accumulation via the Bile Acid-FXR-SHP/PXR Pathway to Regulate Cholesterol Conversion and Fatty Acid Metabolism in Insulin-Resistant Mice.
Li Y; Tian Y; Cai W; Wang Q; Chang Y; Sun Y; Dong P; Wang J
J Agric Food Chem; 2021 Sep; 69(34):9813-9821. PubMed ID: 34415766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
